I. Pedley

发表

Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial

D. Dearnaley, C. Parker, M. Mason, 2022, The Lancet. Oncology.

Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer

C. Ponting, A. Heger, D. Sims, 2014, BMC Cancer.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array

J. R. Wilson, David M. Holden, P. W. Foster, 2016, British Journal of Cancer.

Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol

D. Howel, J. Staffurth, I. Pedley, 2019, BMJ Open.

Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life.

I. Pedley, R. McMenemin, R. Pearson, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)

Catherine J. Grey, Susan N Moore, P. Fayers, 2022, Bju International.

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Warren C. Grant, M. Parmar, M. Sydes, 2021, The Lancet.

Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial

I. Pedley, S. Crabb, E. Clark, 2022, NIHR open research.

Delays in the diagnosis and treatment of muscle invasive bladder cancer: A pilot project mapping the pathway

I. Pedley, R. Heer, R. Pickles, 2015 .

Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy

Andreas Heger, Chris P. Ponting, Owen J. Sansom, 2014, European urology.

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

M. Parmar, M. Sydes, D. Dearnaley, 2018, The Lancet.

Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.

T. Hickish, I. Pedley, Robert J. Jones, 2014, Future oncology.

Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.

James M. Wilson, P. Rajan, I. Pedley, 2015, Urologic oncology.

Systemic chemotherapy and its implications for resection of colorectal liver metastasis.

I. Pedley, D. Mann, D. Manas, 2011, Surgical oncology.

The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting.

I. Pedley, V. Allgar, A. Whitehead, 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life

Joyce E. Wilkinson, T. Peters, P. Fayers, 2016, BJU international.

Tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone-naive, high-risk/metastatic prostate cancer: A phase II, open-labeled, randomized study.

I. Pedley, N. Soomro, H. Leung, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

M. Parmar, M. Sydes, D. Dearnaley, 2023, The Lancet. Oncology.

Magnetic Resonance-only Workflow: Implementation in a UK Centre.

I. Pedley, N. Richmond, J. Wyatt, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

Transperineal interstitial permanent prostate brachytherapy for carcinoma of the prostate.

I. Pedley, 2002, Surgical oncology.

LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol

M. Sydes, C. Parker, N. James, 2021, Annals of Oncology.

ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK.

D. Cunningham, P. Ross, I. Pedley, 2019, Clinical colorectal cancer.

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.

T. Peters, P. Fayers, D. Aston, 2019, European urology.

Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance.

Susan N Moore, P. Fayers, D. Aston, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)

D. Aston, J. Oxley, F. Hamdy, 2022, BJU international.

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life

Joyce E. Wilkinson, T. Peters, P. Fayers, 2016, BJU international.

Edinburgh Research Explorer Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments

D. Aston, F. Hamdy, S. Bhattarai, 2022 .

. Patient-reported outcomes in the ProtecT randomised trial of clinically localised prostate cancer treatments: study design and baseline urinary, bowel and sexual function and quality of life

D. Aston, F. Hamdy, S. Bhattarai, 2022 .

An update on clinical outcome data for a phase II randomized study comparing androgen deprivation therapy plus docetaxel versus androgen deprivation therapy alone in men with locally advanced/metastatic hormone sensitive prostate cancer.

I. Pedley, R. McMenemin, A. Azzabi, 2017 .

A Systematic Review of Population-Based Studies of Chronic Bowel Symptoms in Cancer Survivors following Pelvic Radiotherapy

I. Pedley, H. Ludlow, B. Rimmer, 2023, Cancers.

Late Onset Classical Seminoma in a Sib Pair with Possible Familial Aetiology

M. Robinson, I. Pedley, B. Gowardhan, 2002, Scandinavian journal of urology and nephrology.

Prostate Ultrahypofractionation – Rising to Challenges Presents Opportunities in the COVID-19 Era

I. Pedley, R. Chandler, R. Pearson, 2020, Clinical Oncology.